Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program.
about
Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndromeRETRACTED: XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumorsTherapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolveInfluence of Immune Myeloid Cells on the Extracellular Matrix During Cancer MetastasisSingle and Multiple Gene Manipulations in Mouse Models of Human CancerTherapeutic potential of chemokine signal inhibition for metastatic breast cancerMechanisms of age-related macular degenerationMathematical models of the steps involved in the systemic delivery of a chemotherapeutic to a solid tumor: From circulation to survivalRacial and ethnic differences in risk of second primary cancers among breast cancer survivorsPG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma modelInteraction between Chronic Inflammation and Oral HPV Infection in the Etiology of Head and Neck CancersTherapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemiaSimilar in vitro maturation rates of oocytes retrieved during the follicular or luteal phase offer flexible options for urgent fertility preservation in breast cancer patientsChange in peripheral blood leukocyte telomere length and mortality in breast cancer survivorsComprehensive review of BAP1 tumor predisposition syndrome with report of two new casesPrioritizing therapeutics for lung cancer: an integrative meta-analysis of cancer gene signatures and chemogenomic dataUtilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myelomaA novel KLF6-Rho GTPase axis regulates hepatocellular carcinoma cell migration and disseminationDescriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence.Current Practice Patterns Regarding the Conduct of Thyroidectomy and Parathyroidectomy amongst Surgeons - A Survey StudyAssessing progress in reducing the burden of cancer mortality, 1985-2005.Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysisIncrease in mammography detected breast cancer over time at a community based regional cancer center: a longitudinal cohort study 1990-2005The impact of thyroid cancer and post-surgical radioactive iodine treatment on the lives of thyroid cancer survivors: a qualitative study.Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer.German cancer statistics 2004.Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors.Severe Unresponsive Hypoglycemia Associated with Neuroendocrine Tumor of Unknown Primary Site - 18 Years after Rectal Cancer Surgery. Case Report.MicroRNAs in pathogenesis of breast cancer: Implications in diagnosis and treatment.Female breast cancer survival in Qidong, China, 1972-2011: a population-based studyClinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumorsUncertainty and psychological adjustment in patients with lung cancer.Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations.CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patientCancer survival in Qidong between 1972 and 2011: A population-based analysis.Racial differences in the perception of lung cancer: the 2005 Health Information National Trends SurveySweating the small stuff: microRNAs and genetic changes define pancreatic cancer.Activation of NAG-1 via JNK signaling revealed an isochaihulactone-triggered cell death in human LNCaP prostate cancer cells.Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand?New insights in risk stratification of differentiated thyroid cancer.
P2860
Q21090022-0F5F8143-2447-4B27-9BF0-0B81CAAF5863Q24658112-376026F0-AF16-4C90-8256-E4A93E65BB45Q26764947-D85FC71D-ABD6-4CFE-8CA4-F2467B4C17D3Q26767150-131C7166-5E69-4DE4-A96A-D635E57885CEQ26783920-A5436F1D-3F8F-4C16-84FB-CCA84F7681F0Q26798116-58C743F5-51CF-4DC6-8DD6-6D7386C8274CQ27000182-CF474ED0-8BD7-4D6F-B2F3-570F0516F10CQ27023583-B028113B-720E-4CA7-A896-BA74A62BF266Q27317129-0FFEAC2A-0D54-4A88-B63C-18C541629041Q27327191-E6F55460-8DD0-4FD0-890D-4CFEF73E06B8Q27495979-00CEE3B2-41D3-4FEA-B0BF-F11001A5AF52Q28087378-2ABAF000-7D2E-491A-9F82-1608C6F743F8Q28271961-9B09B513-55E4-406D-A545-894290EE292BQ28383779-A6367D30-E2AE-493C-8522-821DF5AFB395Q28397229-1E5F93D2-010D-4C5A-B81B-3C5115844045Q28544631-E4012879-6726-4DA0-A1B5-1B5FDC3D3343Q28544663-65F6C1BF-2AB3-43B4-90E7-D5247EF224ABQ28597820-6FF25938-C297-4A9D-BD1B-A7A74BE541A8Q30248287-AC32720C-7686-4905-B076-21724DCE7394Q30467499-50DE8542-F861-4FA1-9FCA-3C65B78C8CD4Q30570624-07DF17C9-D994-429D-831D-0A9334DC382DQ30897591-3CC4E840-9E0E-45F0-9084-9612E17B8E2CQ33333655-F6470E1B-F2C7-416E-92B8-88E906145794Q33399709-5F2577D0-7A52-41E9-B5D0-371C27BE4DECQ33408664-802349D8-59C7-48F8-985D-41626CA22A06Q33533451-0B65DC0A-BB94-4E6D-BF6C-BB20B9DC24B3Q33570096-3C474488-84E7-4B34-867B-69A86A0AF12DQ33572417-4CCC553C-35C7-40B9-B544-3ED4C6326530Q33585094-7AB73CD2-055A-4528-9FC6-1DB645D85035Q33593703-16EB5B3F-25DD-45FF-B9BE-5E536153A314Q33627289-3D4106AD-838A-48B2-94B6-FF158EB3E38AQ33678798-3B2EF651-DEE5-4491-92B3-2C1CF5579E5FQ33691512-E690DD73-C9A4-4810-81DE-CCD1DE03BC45Q33728102-7F23B191-BDE0-4837-B3C5-EA2AE364EF7BQ33748254-F708FACC-8243-4EFB-ABF7-E78E89FEF8A2Q33790312-1374387F-E19B-4C4A-BBBA-1137C16460E1Q33862088-8AB0F794-B4AC-4CD2-AFAC-3FCEF8AB4B13Q33877005-58B5A45E-62DA-4C0B-BF3E-01D3424EFC36Q33915293-E1763737-BA8E-45CD-97C4-0CE1DAAE7426Q33915384-61208801-08B2-4A5C-9FDF-8499DF2D97D7
P2860
Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Cancer statistics, trends, and ...... nd End Results (SEER) Program.
@en
type
label
Cancer statistics, trends, and ...... nd End Results (SEER) Program.
@en
prefLabel
Cancer statistics, trends, and ...... nd End Results (SEER) Program.
@en
P2093
P1433
P1476
Cancer statistics, trends, and ...... nd End Results (SEER) Program.
@en
P2093
Brenda K Edwards
Marsha E Reichman
Matthew J Hayat
Nadia Howlader
P356
10.1634/THEONCOLOGIST.12-1-20
P577
2007-01-01T00:00:00Z